Humira vs Biktarvy
Side-by-side drug price comparison from Medicare Part D data
Verdict
Humira costs 9% less per claim than Biktarvy ($3414.00 vs $3746.00). Humira has a generic alternative available. Total Medicare spending: Humira at $6.5B vs Biktarvy at $3.8B.
| Metric | Humira | Biktarvy |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $3,414* | $3,746 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $6.5B | $3.8B |
| Total Claims | 1,890,000 | 1,020,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -22.1%* | 12.8% |
| Generic Available | Yes | No |
| Condition | Autoimmune Diseases | HIV |
| Total Beneficiaries | 195,000 | 85,000 |
Humira costs 9% less per claim than Biktarvy ($3414.00 vs $3746.00). Humira has a generic alternative available. Total Medicare spending: Humira at $6.5B vs Biktarvy at $3.8B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Humira and Biktarvy. What follows is the interpretation — which specific axes carry the most weight for Humira versus Biktarvy, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.